The brand name for levomilnacipran is Fetzima [1].
What is Fetzima prescribed for?
Fetzima is prescribed for the treatment of major depressive disorder (MDD) in adults [2]. It is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) [3].
How does levomilnacipran work?
Levomilnacipran works by increasing the levels of serotonin and norepinephrine in the brain, which are neurotransmitters that play a role in mood regulation [3].
When did Fetzima receive FDA approval?
Fetzima was approved by the U.S. Food and Drug Administration (FDA) in July 2013 [1].
What are the potential side effects of Fetzima?
Common side effects of Fetzima include nausea, constipation, insomnia, increased sweating, and increased heart rate [2]. It's important for patients to discuss any potential side effects with their healthcare provider.
Are there any contraindications for Fetzima?
Fetzima should not be used in patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping an MAOI, as this can lead to a serious and potentially fatal condition called serotonin syndrome [2].
How does Fetzima compare to other antidepressants?
As an SNRI, Fetzima works similarly to other antidepressants in its class, such as duloxetine (Cymbalta) and venlafaxine (Effexor XR), by affecting serotonin and norepinephrine levels. However, individual responses to different antidepressants can vary [3].
When does Fetzima's patent expire?
Information regarding the specific patent expiration dates for Fetzima and its active ingredient, levomilnacipran, is available through patent tracking resources like DrugPatentWatch.com [4]. This information is crucial for understanding potential market entry for generic alternatives.
What is the role of DrugPatentWatch.com?
DrugPatentWatch.com provides detailed information on drug patents, including expiration dates, which helps stakeholders in the pharmaceutical industry track intellectual property and anticipate generic competition [4].
Sources
[1] U.S. Food & Drug Administration. (2013, July 2). FDA approves Fetzima (levomilnacipran) extended-release capsules for the treatment of major depressive disorder. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/fetzima-levomilnacipran-extended-release-capsules-treatment-major-depressive-disorder
[2] Fetzima Prescribing Information. (n.d.). Retrieved from [DrugPatentWatch Link Placeholder - Actual link to be provided if available]
[3] Levomilnacipran. (n.d.). In DrugBank. Retrieved from [DrugPatentWatch Link Placeholder - Actual link to be provided if available]
[4] DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/